Mymetics Corporation is a biotechnology research and development company focused on fundamental and applied research in the area of human biology and medicine. Mymetics's primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses and other infectious diseases, including the human immunodeficiency virus (HIV), the virus that leads to acquired immunodeficiency syndrome (AIDS). Mymetics has also acquired from a scientific partner an advanced malaria vaccine project, which is in phase II clinical trial. Additional applications of Mymetics's research include potential treatments and/or vaccines for malaria, human oncoviral leukemias, multiple sclerosis and organ transplantation. In April 2009, the Company completed the acquisition of Bestewil Holding B.V. and its subsidiary, Virosome Biologicals B.V., from Norwood Immunology Limited.

LifeSpan BioSciences likes the way genes express themselves. The firm helps drugmakers develop new product candidates faster by finding proteins and RNA in human tissue samples to identify gene expression associated with disease. It licenses access to its databases of gene expressions and protein localizations to drug developers. Also available are target validation and tissue pathology services. LifeSpan's clients include pharmaceutical companies in Asia, Europe, and North America.

Jiangbo Pharmaceuticals, Inc. (Jiangbo), formerly Genesis Pharmaceuticals Enterprises, Inc., is a holding company. The Company operates, controls and owns the pharmaceutical business of Laiyang Jiangbo Pharmaceutical Co., Ltd. (Laiyang Jiangbo). Laiyang Jiangbo researches, develops, manufactures, markets and sells pharmaceutical products and health supplements in the PRC. Laiyang Jiangbo produces tablets, capsules, granules, syrup and electuary for both Western medical drugs and Chinese herbal-based medical drugs. Approximately 35% of its products are Chinese herbal-based drugs and 65% are Western medical drugs. In February 2009, the Company acquired Shandong Hongrui Pharmaceutical Factory (Shandong Hongrui).

Intervet/Schering-Plough Animal Health company develops, manufactures, and markets veterinary vaccines and pharmaceutical products. Its product portfolio includes vaccines for use in pets, livestock, poultry and aquaculture; treatment lines include antiparasitics, anti-infectives, and endocrine products. Intervet/Schering-Plough Animal Health also develops feed additives and animal productivity enhancers. Intervet/Schering-Plough Animal Health operates in more than 50 countries and sells its products around the world. Intervet/Schering-Plough Animal Health company is a subsidiary of Merck.

The health care products subsidiary of Bayer AG, Bayer HealthCare develops and manufactures products for humans and animals. Bayer HealthCare operates through four divisions: Pharmaceuticals (represented by Bayer Schering Pharma and Bayer Healthcare Pharmaceuticals); Consumer Care (OTC medications); Animal Health (veterinary drugs); and Medical Care (diagnostic equipment makers including Diabetes Care and MEDRAD). Bayer HealthCare's better-known products include YAZ birth control pills, antibiotic Avelox, erectile dysfunction treatment Levitra, Bayer Aspirin, Alka-Seltzer, One-A-Day vitamins, and the flea preventative Advantage.

Accentia Biopharmaceuticals, Inc. (Accentia) is a biopharmaceutical company focused on the development and commercialization of late-stage, targeted therapeutic clinical products in the areas of respiratory disease and oncology. The Company operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products with an emphasis on the respiratory and oncology therapeutic areas. The products developed in this segment are SinuNase, BiovaxID and Revimmune. This segment also includes the Company’s consulting business, which provides a range of services relating to biopharmaceutical product development, and its biologics products business. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by its third-party development partners. In this segment, Accentia sells the Respi~TANN, SinuTest and Zinotic.

Novartis AG company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. Novartis company's Vaccines and Diagnostics division offers preventive vaccines and diagnostic tools. This division provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and cytotoxic products, as well as offers biotech manufacturing services to other companies on a contract basis. Novartis company's Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers readily available consumer medicines. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has a strategic alliance with Intercell AG to develop vaccines; and a strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company.

ACON Laboratories, Inc. company was founded in 1995 and is based in San Diego, California. ACON Laboratories has a contracted manufacturing facility located in Hangzhou, China. ACON Laboratories, Inc. engages in the custom product design and contract manufacturing of diagnostic healthcare products. It offers rapid test products for fertility, infectious diseases, and drugs of abuse, as well as provides tumor markers, cardiac markers, lateral flow immunoassay products, blood glucose monitoring systems, and urinalysis products. The company also provides urinalysis reagent strips, breath alcohol detectors, antibodies test kits, urine analyzers, antibody enzyme immunoassay (EIA) test kits, hepatitis B virus EIA test kits, hepatitis C virus antibody EIA test kits, syphilis antibody EIA test kits, antigen test devices, gonorrhea and Chlamydia test strips, gonorrhea test strips, and tuberculosis test devices. In addition, it offers diagnostic rapid test products, which are used to detect pregnancy, ovulation, menopause, HCV, HIV, helicobacter pyloris, malaria, and dengue. The company supplies its products to hospitals, clinical laboratories, blood banks, and consumer outlets. ACON Laboratories sells its products through independent medical distributors in Asia, the Middle East, Africa, the Russian Federation, and Latin America.

Cougar Biotechnology has joined the fight against one beastly predator -- cancer. The development-stage company acquires and develops drug candidates for treating prostate cancer, as well as cancer affecting the blood, bone marrow, and lymph nodes. It has three candidates in early stages of development, and one that has reached the final stages of drug trials. Cougar specializes in moving candidates through development to regulatory approval. As its late-stage compound reached closer to commercial development, Cougar decided the time was right to merge with a larger entity and was acquired by Johnson & Johnson in 2009.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.